Background: This is a randomized, superiority, double blind, placebo-controlled, multicenter study comparing evolocumab 420mg SC vs. placebo administered in the acute phase of ACS. The aim is to evaluate the effectiveness of the PCSK9 inhibitor evolocumab as compared with placebo for reduction of LDL-C levels within 8 weeks in patients receiving guideline-recommended high-intensity statin treatment (atorvastatin 40mg QD). Sponsor: Inselspital Bern, Prof. Dr. Stephan Windecker Trial Registration No: NCT03287609 ( Link Trial Status: recruiting Enrolling Centers: Bern, Basel, Fribourg, Genf, Lausanne, Lugano, Zürich Core Study Team:
© Christian Mueller, 2012 - 2024 │ DisclaimerImprintWebmaster │ Last Update: July 2024
Ina-Maria Ferel, Ph.D.